Ciphergen Announces Publication Of Data Describing Application For Evaluating Patients With Blood Disorder

Ciphergen Biosystems, Inc. (Nasdaq: CIPH) today announced that its clinical development partner Ohio State University published an article describing the use of Surface Enhanced Laser Desorption/Ionization Time of Flight (SELDI-TOF) mass spectrometry for the diagnosis and clinical evaluation of thrombotic thrombocytopenic purpura (TTP), a hematologic disease. The article appears in the current issue of Spectroscopy.

"A diagnostic test that can rapidly determine enzyme activity is needed to help clinicians make the correct diagnosis, initiate timely therapy and predict the risk of the disease recurrences for patients with thrombotic thrombocytopenic purpura, a devastating hematological disorder," said Haifeng M. Wu, M.D., Assistant Professor of Pathology and Medicine and Director of Clinical Coagulation Laboratory at Ohio State University Medical Center, author of the paper and Ciphergen collaborator. "This study successfully illustrates the unique application of SELDI-TOF mass spectrometry for measuring enzyme activity and evaluating auto-antibody activity -- both of which are key parameters in the pathology and progression of TTP."

In November 2006, Ciphergen and OSU announced a collaborative agreement to develop and clinically validate a diagnostic test to detect TTP. Under the terms of the agreement, and Ciphergen will optimize the assay to measure enzyme and antibody inhibition activity, and will jointly conduct multi-center studies to validate the test. Ciphergen Biosystems and Ohio State University intend to validate the assay's clinical utility using SELDI-TOF technology across a larger patient population.

About Thrombotic Thrombocytopenic Purpura (TTP)

TTP is a blood disorder characterized by low platelets, low red blood cell count (caused by premature breakdown of the cells), neurological abnormalities and sometimes abnormalities in kidney function. In most cases, this disease is caused by a deficiency in or auto-antibodies to an enzyme called ADAMTS13, which cleaves von Willebrand Factor. Loss of this enzyme causes platelet clumping and red blood cell destruction that are the hallmarks of TTP.

About Ciphergen

Ciphergen Biosystems, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Ciphergen, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology/hematology, cardiology and women's health with an initial focus in ovarian cancer. Based in Fremont, California, more information about Ciphergen can be found on the Web at http://www.ciphergen.com.

Safe Harbor Statement

This press release contains forward-looking statements. For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the utility of using SELDI-TOF mass spectrometry for measuring enzyme activity and evaluating auto-antibody activity and Ciphergen's efforts to optimize an assay for such measurements to be used in a diagnostics test. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the possibility that Ciphergen's efforts may not proceed as anticipated. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-Q filed November 20, 2006, for further information regarding these and other risks related to the Company's business.

Ciphergen Biosystems, Inc.
http://www.ciphergen.com